A portable system that cools the brain via the nasal cavity could increase the survival rate of people who have had a heart attack, according to a study.
The RhinoChill Intra-Nasal Cooling System sprays a coolant liquid into the nasal cavity using a non-invasive catheter.
Cooling the brain after cardiac arrest reduces its need for oxygen, which could help to prevent brain injuries.
The European study involved 200 people who suffered cardiac arrest and CPR was initiated within 20 minutes of collapse.
The patients received either intra-nasal cooling with RhinoChill along with standard advanced cardiac life support (ACLS) care or ACLS alone, until they were either resuscitated or reached hospital.
The study results showed that RhinoChill helped the patients to achieve target brain temperature of 34°C three hours earlier, and the target body temperature was achieved two hours earlier.
The survival rate of patients receiving RhinoChill was 47% compared to 31% in patients who did not receive it.
About 37% of the patients who received RhinoChill survived neurologically intact, compared to 21% of patients who did not receive RhinoChill.
The RhinoChill System has received a CE mark approval, and is expected to launch in European markets in October 2010.